ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment
Beau Bosko Toskich, Professor of Radiology, Director of Interventional Oncology, Mayo Clinic Florida, shared a post by Peter Pattison on X, adding:
”Deepest gratitude to ROWAN trial patients and our global investigators for pushing HCC treatment forward! Your passion and dedication is driving real progress.”
Quoting Peter Pattison’s post:
”Big news from the ROWAN study! We’ve officially completed enrollment, marking a major step forward in understanding the potential enhanced clinical benefits of combining TheraSphere with the immunotherapy STRIDE regimen in patients with Hepatocellular Carcinoma. This milestone brings us closer to understanding how we can better support patients through innovative, targeted therapies. Learn more about the ROWAN study here.”
More posts featuring Beau Bosko Toskich.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023